These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30573026)

  • 1. Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.
    Ghorbani A; Bhambhani V; Christenson RH; Meijers WC; de Boer RA; Levy D; Larson MG; Ho JE
    J Am Coll Cardiol; 2018 Dec; 72(25):3246-3254. PubMed ID: 30573026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.
    Ho JE; Liu C; Lyass A; Courchesne P; Pencina MJ; Vasan RS; Larson MG; Levy D
    J Am Coll Cardiol; 2012 Oct; 60(14):1249-56. PubMed ID: 22939561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study.
    Aguilar D; Sun C; Hoogeveen RC; Nambi V; Selvin E; Matsushita K; Saeed A; McEvoy JW; Shah AM; Solomon SD; Boerwinkle E; Ballantyne CM
    J Am Heart Assoc; 2020 Jul; 9(13):e015405. PubMed ID: 32573308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study.
    Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E
    Am Heart J; 2014 May; 167(5):674-82.e1. PubMed ID: 24766977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community.
    Nayor M; Wang N; Larson MG; Vasan RS; Levy D; Ho JE
    J Am Heart Assoc; 2015 Dec; 5(1):. PubMed ID: 26722123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Validation of a Screening Biomarker Approach Combining Amino-Terminal Pro-Brain Natriuretic Peptide With Galectin-3 Predicts Death and Cardiovascular Events in Asymptomatic Hemodialysis Patients.
    Voroneanu L; Siriopol D; Apetrii M; Hogas S; Onofriescu M; Nistor I; Kanbay M; Dumea R; Cusai S; Cianga P; Constantinescu D; Covic A
    Angiology; 2018 May; 69(5):449-455. PubMed ID: 28974104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
    Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
    J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
    Jagodzinski A; Havulinna AS; Appelbaum S; Zeller T; Jousilahti P; Skytte-Johanssen S; Hughes MF; Blankenberg S; Salomaa V
    Int J Cardiol; 2015 Aug; 192():33-9. PubMed ID: 25985013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial galectin-3 and future cardiovascular disease in the general population.
    van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA
    Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study.
    Asleh R; Enriquez-Sarano M; Jaffe AS; Manemann SM; Weston SA; Jiang R; Roger VL
    J Am Coll Cardiol; 2019 May; 73(18):2286-2295. PubMed ID: 31072572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
    Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
    BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin 3 and incident atrial fibrillation in the community.
    Ho JE; Yin X; Levy D; Vasan RS; Magnani JW; Ellinor PT; McManus DD; Lubitz SA; Larson MG; Benjamin EJ
    Am Heart J; 2014 May; 167(5):729-34.e1. PubMed ID: 24766984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients.
    Hogas S; Schiller A; Voroneanu L; Constantinescu D; Timar R; Cianga P; Siriopol D; Bob F; Cianga C; Onofriescu M; Gadalean F; Hogas M; Mihaescu A; Bilha SC; Timar B; Kanbay M; Banach M; Covic A
    Angiology; 2016 Oct; 67(9):854-9. PubMed ID: 26787685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.
    Francia P; Adduci C; Semprini L; Borro M; Ricotta A; Sensini I; Santini D; Caprinozzi M; Balla C; Simmaco M; Volpe M
    J Cardiovasc Electrophysiol; 2014 Jun; 25(6):609-16. PubMed ID: 24400815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes.
    Tan KCB; Cheung CL; Lee ACH; Lam JKY; Wong Y; Shiu SWM
    Diabetes Metab Res Rev; 2019 Feb; 35(2):e3093. PubMed ID: 30378236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease.
    Maiolino G; Rossitto G; Pedon L; Cesari M; Frigo AC; Azzolini M; Plebani M; Rossi GP
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):725-32. PubMed ID: 25614283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
    Patel DM; Thiessen-Philbrook H; Brown JR; McArthur E; Moledina DG; Mansour SG; Shlipak MG; Koyner JL; Kavsak P; Whitlock RP; Everett AD; Malenka DJ; Garg AX; Coca SG; Parikh CR
    Am Heart J; 2020 Feb; 220():253-263. PubMed ID: 31911262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population.
    Imran TF; Shin HJ; Mathenge N; Wang F; Kim B; Joseph J; Gaziano JM; Djoussé L
    Am J Cardiol; 2017 Jan; 119(1):57-64. PubMed ID: 28247849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.